Search Results

You are looking at 11 - 20 of 1,415 items for :

  • "carcinoma" x
  • Refine by Access: All x
Clear All
Full access

Role of Radiotherapy in the Management of Merkel Cell Carcinoma of the Skin

Roy H. Decker and Lynn D. Wilson

treatment of Merkel cell carcinoma: case series and literature review of 1024 cases . Ann Surg Oncol 2001 ; 8 : 204 – 208 . 2. Gillenwater AM Hessel AC Morrison WH . Merkel cell carcinoma of the head and neck: effect of surgical excision and

Full access

Milestones in the Staging, Classification, and Biology of Merkel Cell Carcinoma

Ata S. Moshiri and Paul Nghiem

Merkel cell carcinoma (MCC), or primary neuroendocrine carcinoma of the skin, is an aggressive cutaneous malignancy with 3 times the disease-specific mortality of melanoma (46% vs 15%). 1 The annual incidence is approximately 1500 cases in the

Full access

Targeting the NTRK Fusion Gene in Pancreatic Acinar Cell Carcinoma: A Case Report and Review of the Literature

Medhavi Gupta, Christopher Sherrow, Maghan E. Krone, Edik M. Blais, Michael J. Pishvaian, Emanuel F. Petricoin III, Lynn M. Matrisian, Patricia DeArbeloa, Gary Gregory, Alyson Brown, Olivia Zalewski, Gillian Prinzing, Charles Roche, Kazunori Kanehira, Sarbajit Mukherjee, Renuka Iyer, and Christos Fountzilas

Background Pancreatic acinar cell carcinoma (PACC) is a rare exocrine pancreas malignancy, accounting for <1% of primary pancreatic neoplasms. Compared with pancreatic ductal adenocarcinoma (PDAC), PACC affects mostly younger male White patients. 1

Full access

NCCN Task Force Report: Optimizing Treatment of Advanced Renal Cell Carcinoma With Molecular Targeted Therapy

Gary R. Hudes, Michael A. Carducci, Toni K. Choueiri, Peg Esper, Eric Jonasch, Rashmi Kumar, Kim A. Margolin, M. Dror Michaelson, Robert J. Motzer, Roberto Pili, Susan Roethke, and Sandy Srinivas

cases consist of renal cell carcinomas (RCCs), which are genetically and histologically distinct from cancers of the renal pelvis. An increased understanding of RCC biology coupled with new clinical trials data have resulted in the availability of

Full access

Genetic Kidney Cancer Syndromes

Thai H. Ho and Eric Jonasch

Hereditary renal cell carcinoma (RCC) has been estimated to account for 5% to 8% of all RCC cases, and extrarenal manifestations may present as early as 3 years of age ( Table 1 ). 1 , 2 RCC is a diverse set of cancers that originate from the

Full access

Treatment Patterns and Outcomes in Patients With Hepatocellular Carcinoma Stratified by Stage-Guided Treatment Categories

Kuan-Ling Kuo, David Stenehjem, Frederick Albright, Saurabh Ray, and Diana Brixner

Background Hepatocellular carcinoma (HCC) is a primary malignancy of the liver. The American Cancer Society estimates that 33,190 new cases for primary liver cancer and intrahepatic bile duct cancer were diagnosed in 2014 in the United States

Full access

Anal Carcinoma

Paul F. Engstrom, Juan Pablo Arnoletti, Al B. Benson III, Jordan D. Berlin, J. Michael Berry, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Raza A. Dilawari, Dayna S. Early, Peter C. Enzinger, Marwan G. Fakih, James Fleshman Jr., Charles Fuchs, Jean L. Grem, James A. Knol, Lucille A. Leong, Edward Lin, Mary F. Mulcahy, Eric Rohren, David P. Ryan, Leonard Saltz, David Shibata, John M. Skibber, William Small Jr., Constantinos Sofocleous, James Thomas, Alan P. Venook, and Christopher Willett

Anal Carcinoma Clinical Practice Guidelines in Oncology NCCN Categories of Evidence and Consensus Category 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN consensus

Full access

Risk Reduction Strategies for Ductal Carcinoma In Situ

Adam L. Cohen and John H. Ward

D uctal carcinoma in situ (DCIS) is “a proliferation of malignant epithelial cells within the breast parenchymal structures with no evidence of invasion across the basement membrane.” 1 It is one fourth as common as invasive breast cancer, with

Full access

Thyroid Carcinoma, Version 2.2014

R. Michael Tuttle, Robert I. Haddad, Douglas W. Ball, David Byrd, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Megan Haymart, Carl Hoh, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Peter Kopp, Dominick M. Lamonica, William M. Lydiatt, Judith McCaffrey, Jeffrey F. Moley, Lee Parks, Christopher D. Raeburn, John A. Ridge, Matthew D. Ringel, Randall P. Scheri, Jatin P. Shah, Steven I. Sherman, Cord Sturgeon, Steven G. Waguespack, Thomas N. Wang, Lori J. Wirth, Karin G. Hoffmann, and Miranda Hughes

, participants will be able to: Integrate into professional practice the updates to NCCN Guidelines for Thyroid Carcinoma Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Thyroid Carcinoma

Full access

Anal Carcinoma, Version 2.2012

Featured Updates to the NCCN Guidelines

Al B. Benson III, J. Pablo Arnoletti, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Raza A. Dilawari, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, James W. Fleshman Jr., Charles S. Fuchs, Jean L. Grem, Lucille A. Leong, Edward Lin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr., Constantinos T. Sofocleous, Alan P. Venook, Christopher Willett, and Deborah A. Freedman-Cass

Anal Carcinoma, Version 2.2012 Version 2.2012 © National Comprehensive Cancer Network, Inc. 2012, All rights reserved. The NCCN Guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN